Figure 1

Convalescent plasma therapy in aHUS patient with SARS-CoV-2 infection

Emma Diletta Stea*, Virginia Pronzo, Francesco Pesce, Marco Fiorentino, Adele Mitrotti, Vincenzo Di Leo, Cosma Cortese, Annalisa Casanova, Sebastiano Nestola, Flavia Capaccio and Loreto Gesualdo

Published: 22 April, 2022 | Volume 6 - Issue 1 | Pages: 036-039

jcn-aid1088-g001

Figure 1:

A) Trend of inflammatory markers: CRP line blue; IL-6-line gray. The red arrows indicate the hyper-immune plasma administration (between 7th to 9th of November). The patient presents two distinct infection peaks. During the first peak bacterial super-infection was not detected and the X-ray confirmed a COVID-19 pneumonia. CRP and IL-6 showed a significant decrease after the plasma infusion until the 28/29th of November when the patient developed a bacterial infection of the central venous catheter. B) Trend of PO2-FiO2 ratio. The patient developed a severe and fast decrease of P/F ratio requiring a ventilatory support since the 4th of November (CPA PEEP 8 cmH20 FiO2 80% - 100%). Hyper-immune plasma was administrated between 7th to 9th of November. There was an improvement of PO2/FiO2 ratio: from 84, at the beginning of the therapy, to 224 on the 3rd day of plasma administration without other ventilation change. The PO2-FiO2 ratio showed a slightly decrease between the 10th - 20th of November corresponding to a gradually ventilator weaning and recovery of the spontaneous breathing. On the top of the pictures, the two lines represent the concomitant medications. Pink line: i.v. dexamethasone (6 mg once daily for 16 days followed by a fast tapering) which had been administered since the admission. Blue line: i.v. Ceftriaxone that was added when clinical symptoms worsened. The “x” represents the time of first negative nasopharyngeal swab for SARS-CoV-2.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001088 Cite this Article Read Full Article PDF

More Images

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?